— Biotest Unveils New Paradigm in Rapid Testing, Opening a Chapter on Precision Diagnostics

From February 10th to 13th, 2026, in the futuristic city of Dubai, WHX Labs Dubai 2026 (formerly known as Medlab Middle East) — a grand gathering of the world's top minds and technologies in the global healthcare sector — was held in grandeur.

As an innovation-driven player in the international in vitro diagnostics (IVD) field, Biotest presented its diversified technology portfolio and scenario-based solutions to global clients, showcasing the technological strength and global vision of a Chinese IVD enterprise to the world, becoming one of the most notable highlights of the exhibition.

Technological Iteration, Comprehensive Coverage

Focusing on booth H3.E50, Biotest showcased its full range of product solutions and new R&D matrix. It highlighted a series of innovative products including the FluidicNow™ Microfluidic Immunofluorescence Analysis System, the OralTwist Oral Fluid Drug Screen Test, as well as newly CE IVDR-certified respiratory multiplex detection products.

At the exhibition site, the " FluidicNowTMMicrofluidic Innovation Experience Zone" built around theFluidicNow™ Microfluidic Immunofluorescence Analysis System became the most popular focal area. The booth was filled with a vibrant atmosphere for exchange, fully demonstrating the industry's high level of interest in innovative diagnostic technologies. Through iterations, the platform has achieved breakthroughs in detectable markers and sensitivity. It integrates a high-sensitivity sensing system to accurately capture trace biomarkers and supports rapid multi-marker detection. This technology covers the entire spectrum of scenarios from laboratories and emergency departments to primary care, embodying Biotest's philosophy of "adapting innovative technology to meet all scenario needs."

Deepening Cooperation, Forging the Future Together

The WHX Labs Dubai 2026 exhibition has concluded successfully, but Biotest's global health journey continues to accelerate. Moving forward, Biotest will persist in introducing diagnostic solutions that address unmet clinical needs, contributing "Biotest Wisdom" and "Chinese Strength" to building a global community of health for all.